Editor's Note: Green and red arrows refer to intraday stock price movement.NEW YORK ( TheStreet) -- CHANGE IN RATINGS Affiliated Managers ( AMG) downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Stock is already pricing in higher asset flows. Apollo ( APOL) rated new Buy at Goldman. $54 price target. New enrollment declines should begin to stabilize by the August quarter. Blackstone ( BX) downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Company was also removed from the Conviction List. Valuation call. Carefusion ( CFN) downgraded at BofA/Merrill from Buy to Neutral, Bank of America/Merrill Lynch said. Valuation call, based on a $30 price target. Columbia Sportswear ( COLM) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $70 price target. Sales outlook remains strong. Dr. Pepper Snapple ( DPS) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. $37 price target. Company is facing higher commodity costs. Education Management ( EDMC) downgraded at Goldman to Sell from Neutral, Goldman Sachs said. $18 price target. Company is most exposed to new regulations. Energizer ( ENR) downgraded at UBS from Buy to Neutral, UBS said. $76 price target. Focus on Hydro razor could hurt other divisions. Ensco ( ESV) upgraded at Morgan Stanley from Underweight to Equal-weight, Morgan Stanley said. $75 price target. Stock is pricing in the recent ban in the Gulf of Mexico. Hershey ( HSY) upgraded at Goldman from Sell to Neutral, Goldman Sachs said. Price increases should help drive earnings growth. $59 price target. IBM ( IBM) downgraded at Canaccord from Buy to Hold, Canaccord Genuity said. Valuation call, based on a $180 price target. Jack in the Box ( JACK) downgraded at Credit Suisse to Underperform from Neutral. Overpaying for a post-refranchising business, Credit Suisse said. Price target lowered by a dollar to $20. Janus ( JNS) upgraded at Wells from Market Perform to Outperform. Net outflows should begin to decelerate. Medtronic ( MDT) upgraded at Wells from Market Perform to Outperform. Growth is accelerating. Magellan Health ( MGLN) rated new Underperform at BofA/Merrill. $50 price target. Organic growth will likely lag peers. Monsanto ( MON) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. Valuation call, based on a $78 price target.